nodes	percent_of_prediction	percent_of_DWPC	metapath
Sorafenib—KDR—Integrins in angiogenesis—CSF1—Paget's disease of bone	0.00336	0.0148	CbGpPWpGaD
Sorafenib—KDR—Notch-mediated HES/HEY network—BGLAP—Paget's disease of bone	0.00336	0.0148	CbGpPWpGaD
Sorafenib—KIT—Differentiation Pathway—CSF1—Paget's disease of bone	0.00324	0.0142	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling events mediated by TCPTP—CSF1—Paget's disease of bone	0.0032	0.014	CbGpPWpGaD
Sorafenib—CDK7—G2/M Transition—OPTN—Paget's disease of bone	0.0031	0.0136	CbGpPWpGaD
Sorafenib—CDK7—Mitotic G2-G2/M phases—OPTN—Paget's disease of bone	0.00306	0.0134	CbGpPWpGaD
Sorafenib—MAP3K7—IL1-mediated signaling events—SQSTM1—Paget's disease of bone	0.0029	0.0127	CbGpPWpGaD
Sorafenib—MAP3K7—Downstream TCR signaling—INPP5D—Paget's disease of bone	0.00279	0.0122	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling events mediated by PTP1B—CSF1—Paget's disease of bone	0.00259	0.0114	CbGpPWpGaD
Sorafenib—MAP3K7—RANKL/RANK Signaling Pathway—TNFRSF11B—Paget's disease of bone	0.00256	0.0113	CbGpPWpGaD
Sorafenib—MAP3K7—Interleukin-1 signaling—SQSTM1—Paget's disease of bone	0.00255	0.0112	CbGpPWpGaD
Sorafenib—Abdominal discomfort—Alendronate—Paget's disease of bone	0.00255	0.0033	CcSEcCtD
Sorafenib—Renal failure acute—Pamidronate—Paget's disease of bone	0.00254	0.00329	CcSEcCtD
Sorafenib—Diarrhoea—Tiludronate—Paget's disease of bone	0.00253	0.00328	CcSEcCtD
Sorafenib—MAPK11—IL-4 Signaling Pathway—INPP5D—Paget's disease of bone	0.00248	0.0109	CbGpPWpGaD
Sorafenib—Pain in extremity—Risedronate—Paget's disease of bone	0.00247	0.00319	CcSEcCtD
Sorafenib—RALBP1—EGF/EGFR Signaling Pathway—INPP5D—Paget's disease of bone	0.00245	0.0108	CbGpPWpGaD
Sorafenib—Dizziness—Tiludronate—Paget's disease of bone	0.00245	0.00317	CcSEcCtD
Sorafenib—Cardiac failure—Pamidronate—Paget's disease of bone	0.0024	0.00311	CcSEcCtD
Sorafenib—MAP3K7—TGF-beta receptor signaling—PML—Paget's disease of bone	0.00239	0.0105	CbGpPWpGaD
Sorafenib—Erythema multiforme—Etidronic acid—Paget's disease of bone	0.00236	0.00305	CcSEcCtD
Sorafenib—Stevens-Johnson syndrome—Alendronate—Paget's disease of bone	0.00235	0.00304	CcSEcCtD
Sorafenib—Renal failure acute—Zoledronate—Paget's disease of bone	0.00232	0.003	CcSEcCtD
Sorafenib—Headache—Tiludronate—Paget's disease of bone	0.00232	0.003	CcSEcCtD
Sorafenib—Stomatitis—Alendronate—Paget's disease of bone	0.00231	0.00299	CcSEcCtD
Sorafenib—RAF1—GMCSF-mediated signaling events—INPP5D—Paget's disease of bone	0.0023	0.0101	CbGpPWpGaD
Sorafenib—MAP3K7—TNF receptor signaling pathway —SQSTM1—Paget's disease of bone	0.00228	0.01	CbGpPWpGaD
Sorafenib—Abdominal pain upper—Risedronate—Paget's disease of bone	0.00225	0.00292	CcSEcCtD
Sorafenib—Breast disorder—Risedronate—Paget's disease of bone	0.00223	0.00289	CcSEcCtD
Sorafenib—FGFR1—FGF signaling pathway—BGLAP—Paget's disease of bone	0.00221	0.00972	CbGpPWpGaD
Sorafenib—Nasopharyngitis—Risedronate—Paget's disease of bone	0.0022	0.00286	CcSEcCtD
Sorafenib—Alopecia—Etidronic acid—Paget's disease of bone	0.0022	0.00285	CcSEcCtD
Sorafenib—MAPK11—Regulation of retinoblastoma protein—BGLAP—Paget's disease of bone	0.0022	0.00967	CbGpPWpGaD
Sorafenib—Nausea—Tiludronate—Paget's disease of bone	0.0022	0.00285	CcSEcCtD
Sorafenib—RAF1—Endothelin Pathways—CALCA—Paget's disease of bone	0.00219	0.00963	CbGpPWpGaD
Sorafenib—Gastritis—Risedronate—Paget's disease of bone	0.00218	0.00283	CcSEcCtD
Sorafenib—Erythema—Etidronic acid—Paget's disease of bone	0.00217	0.00281	CcSEcCtD
Sorafenib—BRAF—mTOR signaling pathway—PML—Paget's disease of bone	0.00217	0.00952	CbGpPWpGaD
Sorafenib—Pain in extremity—Zoledronate—Paget's disease of bone	0.00214	0.00277	CcSEcCtD
Sorafenib—Haemoglobin—Alendronate—Paget's disease of bone	0.00214	0.00277	CcSEcCtD
Sorafenib—Hypokalaemia—Pamidronate—Paget's disease of bone	0.00213	0.00276	CcSEcCtD
Sorafenib—Haemorrhage—Alendronate—Paget's disease of bone	0.00213	0.00275	CcSEcCtD
Sorafenib—Nasopharyngitis—Pamidronate—Paget's disease of bone	0.0021	0.00271	CcSEcCtD
Sorafenib—Muscle spasms—Etidronic acid—Paget's disease of bone	0.00209	0.0027	CcSEcCtD
Sorafenib—RAF1—Interleukin-11 Signaling Pathway—BGLAP—Paget's disease of bone	0.00209	0.00917	CbGpPWpGaD
Sorafenib—FGFR1—Endochondral Ossification—ALPL—Paget's disease of bone	0.00209	0.00916	CbGpPWpGaD
Sorafenib—MAP3K7—TCR signaling—INPP5D—Paget's disease of bone	0.00208	0.00915	CbGpPWpGaD
Sorafenib—KIT—Kit receptor signaling pathway—INPP5D—Paget's disease of bone	0.00208	0.00915	CbGpPWpGaD
Sorafenib—Gastritis—Pamidronate—Paget's disease of bone	0.00207	0.00269	CcSEcCtD
Sorafenib—CDK7—Late Phase of HIV Life Cycle—NUP205—Paget's disease of bone	0.00206	0.00904	CbGpPWpGaD
Sorafenib—Abdominal discomfort—Risedronate—Paget's disease of bone	0.00204	0.00265	CcSEcCtD
Sorafenib—Erythema multiforme—Alendronate—Paget's disease of bone	0.00201	0.0026	CcSEcCtD
Sorafenib—Anaemia—Etidronic acid—Paget's disease of bone	0.00201	0.0026	CcSEcCtD
Sorafenib—Dehydration—Zoledronate—Paget's disease of bone	0.00199	0.00258	CcSEcCtD
Sorafenib—Angioedema—Etidronic acid—Paget's disease of bone	0.00198	0.00257	CcSEcCtD
Sorafenib—MAP3K7—RANKL/RANK Signaling Pathway—SQSTM1—Paget's disease of bone	0.00197	0.00867	CbGpPWpGaD
Sorafenib—MAP3K7—IL-1 signaling pathway—SQSTM1—Paget's disease of bone	0.00197	0.00867	CbGpPWpGaD
Sorafenib—Abdominal pain upper—Zoledronate—Paget's disease of bone	0.00196	0.00253	CcSEcCtD
Sorafenib—Hypokalaemia—Zoledronate—Paget's disease of bone	0.00195	0.00252	CcSEcCtD
Sorafenib—Leukopenia—Etidronic acid—Paget's disease of bone	0.00194	0.00252	CcSEcCtD
Sorafenib—Nasopharyngitis—Zoledronate—Paget's disease of bone	0.00191	0.00248	CcSEcCtD
Sorafenib—Pneumonia—Risedronate—Paget's disease of bone	0.00191	0.00247	CcSEcCtD
Sorafenib—Infestation NOS—Risedronate—Paget's disease of bone	0.0019	0.00246	CcSEcCtD
Sorafenib—Infestation—Risedronate—Paget's disease of bone	0.0019	0.00246	CcSEcCtD
Sorafenib—CDK7—HIV Life Cycle—NUP205—Paget's disease of bone	0.0019	0.00834	CbGpPWpGaD
Sorafenib—RAF1—Interleukin-2 signaling—INPP5D—Paget's disease of bone	0.0019	0.00834	CbGpPWpGaD
Sorafenib—MAPK11—p73 transcription factor network—PML—Paget's disease of bone	0.0019	0.00832	CbGpPWpGaD
Sorafenib—Gastritis—Zoledronate—Paget's disease of bone	0.00189	0.00245	CcSEcCtD
Sorafenib—Neutropenia—Pamidronate—Paget's disease of bone	0.00189	0.00245	CcSEcCtD
Sorafenib—MAP3K7—BCR signaling pathway—INPP5D—Paget's disease of bone	0.00188	0.00826	CbGpPWpGaD
Sorafenib—Alopecia—Alendronate—Paget's disease of bone	0.00188	0.00243	CcSEcCtD
Sorafenib—MAPK11—Glucocorticoid receptor regulatory network—BGLAP—Paget's disease of bone	0.00185	0.00813	CbGpPWpGaD
Sorafenib—Erythema—Alendronate—Paget's disease of bone	0.00185	0.0024	CcSEcCtD
Sorafenib—Dysphagia—Zoledronate—Paget's disease of bone	0.00185	0.0024	CcSEcCtD
Sorafenib—Arthralgia—Etidronic acid—Paget's disease of bone	0.00185	0.00239	CcSEcCtD
Sorafenib—RAF1—IL-3 Signaling Pathway—INPP5D—Paget's disease of bone	0.00184	0.00807	CbGpPWpGaD
Sorafenib—Pneumonia—Pamidronate—Paget's disease of bone	0.00182	0.00235	CcSEcCtD
Sorafenib—Dysgeusia—Alendronate—Paget's disease of bone	0.00181	0.00235	CcSEcCtD
Sorafenib—Infestation NOS—Pamidronate—Paget's disease of bone	0.00181	0.00234	CcSEcCtD
Sorafenib—Infestation—Pamidronate—Paget's disease of bone	0.00181	0.00234	CcSEcCtD
Sorafenib—Hepatobiliary disease—Risedronate—Paget's disease of bone	0.0018	0.00233	CcSEcCtD
Sorafenib—Muscle spasms—Alendronate—Paget's disease of bone	0.00178	0.0023	CcSEcCtD
Sorafenib—Renal failure—Pamidronate—Paget's disease of bone	0.00178	0.0023	CcSEcCtD
Sorafenib—Abdominal discomfort—Zoledronate—Paget's disease of bone	0.00177	0.0023	CcSEcCtD
Sorafenib—Infection—Etidronic acid—Paget's disease of bone	0.00176	0.00228	CcSEcCtD
Sorafenib—Stomatitis—Pamidronate—Paget's disease of bone	0.00176	0.00228	CcSEcCtD
Sorafenib—Neutropenia—Zoledronate—Paget's disease of bone	0.00173	0.00224	CcSEcCtD
Sorafenib—Haemoglobin—Risedronate—Paget's disease of bone	0.00171	0.00222	CcSEcCtD
Sorafenib—Anaemia—Alendronate—Paget's disease of bone	0.00171	0.00221	CcSEcCtD
Sorafenib—Haemorrhage—Risedronate—Paget's disease of bone	0.00171	0.00221	CcSEcCtD
Sorafenib—Angioedema—Alendronate—Paget's disease of bone	0.00169	0.00219	CcSEcCtD
Sorafenib—Urinary tract disorder—Risedronate—Paget's disease of bone	0.00168	0.00218	CcSEcCtD
Sorafenib—Connective tissue disorder—Risedronate—Paget's disease of bone	0.00168	0.00217	CcSEcCtD
Sorafenib—Weight decreased—Zoledronate—Paget's disease of bone	0.00167	0.00217	CcSEcCtD
Sorafenib—Urethral disorder—Risedronate—Paget's disease of bone	0.00167	0.00217	CcSEcCtD
Sorafenib—Infestation—Zoledronate—Paget's disease of bone	0.00165	0.00214	CcSEcCtD
Sorafenib—Infestation NOS—Zoledronate—Paget's disease of bone	0.00165	0.00214	CcSEcCtD
Sorafenib—RAF1—AGE/RAGE pathway—ALPL—Paget's disease of bone	0.00163	0.00716	CbGpPWpGaD
Sorafenib—Haemoglobin—Pamidronate—Paget's disease of bone	0.00163	0.00211	CcSEcCtD
Sorafenib—Renal failure—Zoledronate—Paget's disease of bone	0.00162	0.0021	CcSEcCtD
Sorafenib—Haemorrhage—Pamidronate—Paget's disease of bone	0.00162	0.0021	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Etidronic acid—Paget's disease of bone	0.00161	0.00209	CcSEcCtD
Sorafenib—Stomatitis—Zoledronate—Paget's disease of bone	0.00161	0.00208	CcSEcCtD
Sorafenib—Urinary tract disorder—Pamidronate—Paget's disease of bone	0.0016	0.00207	CcSEcCtD
Sorafenib—Connective tissue disorder—Pamidronate—Paget's disease of bone	0.00159	0.00206	CcSEcCtD
Sorafenib—Tinnitus—Risedronate—Paget's disease of bone	0.00159	0.00206	CcSEcCtD
Sorafenib—Urethral disorder—Pamidronate—Paget's disease of bone	0.00159	0.00206	CcSEcCtD
Sorafenib—Cardiac disorder—Risedronate—Paget's disease of bone	0.00158	0.00205	CcSEcCtD
Sorafenib—RAF1—Kit receptor signaling pathway—INPP5D—Paget's disease of bone	0.00158	0.00695	CbGpPWpGaD
Sorafenib—Myalgia—Alendronate—Paget's disease of bone	0.00158	0.00204	CcSEcCtD
Sorafenib—Dyspepsia—Etidronic acid—Paget's disease of bone	0.00156	0.00202	CcSEcCtD
Sorafenib—Angiopathy—Risedronate—Paget's disease of bone	0.00155	0.002	CcSEcCtD
Sorafenib—CDK7—Integrated Breast Cancer Pathway—PML—Paget's disease of bone	0.00154	0.00678	CbGpPWpGaD
Sorafenib—RAF1—Fc-epsilon receptor I signaling in mast cells—INPP5D—Paget's disease of bone	0.00154	0.00677	CbGpPWpGaD
Sorafenib—Immune system disorder—Risedronate—Paget's disease of bone	0.00154	0.002	CcSEcCtD
Sorafenib—Mediastinal disorder—Risedronate—Paget's disease of bone	0.00154	0.00199	CcSEcCtD
Sorafenib—BRAF—B Cell Receptor Signaling Pathway—INPP5D—Paget's disease of bone	0.00154	0.00675	CbGpPWpGaD
Sorafenib—Arrhythmia—Risedronate—Paget's disease of bone	0.00152	0.00197	CcSEcCtD
Sorafenib—MAP2K5—BDNF signaling pathway—ALPL—Paget's disease of bone	0.00152	0.00668	CbGpPWpGaD
Sorafenib—Constipation—Etidronic acid—Paget's disease of bone	0.00152	0.00196	CcSEcCtD
Sorafenib—RAF1—Regulation of retinoblastoma protein—BGLAP—Paget's disease of bone	0.00151	0.00663	CbGpPWpGaD
Sorafenib—Flushing—Pamidronate—Paget's disease of bone	0.0015	0.00195	CcSEcCtD
Sorafenib—Cardiac disorder—Pamidronate—Paget's disease of bone	0.0015	0.00195	CcSEcCtD
Sorafenib—Infection—Alendronate—Paget's disease of bone	0.0015	0.00194	CcSEcCtD
Sorafenib—RAF1—mTOR signaling pathway—PML—Paget's disease of bone	0.0015	0.00659	CbGpPWpGaD
Sorafenib—Mental disorder—Risedronate—Paget's disease of bone	0.00149	0.00194	CcSEcCtD
Sorafenib—Malnutrition—Risedronate—Paget's disease of bone	0.00148	0.00192	CcSEcCtD
Sorafenib—Angiopathy—Pamidronate—Paget's disease of bone	0.00147	0.00191	CcSEcCtD
Sorafenib—Immune system disorder—Pamidronate—Paget's disease of bone	0.00146	0.0019	CcSEcCtD
Sorafenib—Urinary tract disorder—Zoledronate—Paget's disease of bone	0.00146	0.00189	CcSEcCtD
Sorafenib—Mediastinal disorder—Pamidronate—Paget's disease of bone	0.00146	0.00189	CcSEcCtD
Sorafenib—Connective tissue disorder—Zoledronate—Paget's disease of bone	0.00146	0.00188	CcSEcCtD
Sorafenib—Urethral disorder—Zoledronate—Paget's disease of bone	0.00145	0.00188	CcSEcCtD
Sorafenib—Gastrointestinal pain—Etidronic acid—Paget's disease of bone	0.00145	0.00188	CcSEcCtD
Sorafenib—Alopecia—Pamidronate—Paget's disease of bone	0.00143	0.00186	CcSEcCtD
Sorafenib—RAF1—BCR signaling pathway—INPP5D—Paget's disease of bone	0.00143	0.00628	CbGpPWpGaD
Sorafenib—Muscle spasms—Risedronate—Paget's disease of bone	0.00143	0.00185	CcSEcCtD
Sorafenib—Erythema—Pamidronate—Paget's disease of bone	0.00141	0.00183	CcSEcCtD
Sorafenib—Malnutrition—Pamidronate—Paget's disease of bone	0.00141	0.00183	CcSEcCtD
Sorafenib—Urticaria—Etidronic acid—Paget's disease of bone	0.00141	0.00182	CcSEcCtD
Sorafenib—Abdominal pain—Etidronic acid—Paget's disease of bone	0.0014	0.00181	CcSEcCtD
Sorafenib—MAP3K7—B Cell Receptor Signaling Pathway—INPP5D—Paget's disease of bone	0.0014	0.00614	CbGpPWpGaD
Sorafenib—Dysgeusia—Pamidronate—Paget's disease of bone	0.00138	0.00179	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Alendronate—Paget's disease of bone	0.00138	0.00178	CcSEcCtD
Sorafenib—Flushing—Zoledronate—Paget's disease of bone	0.00137	0.00178	CcSEcCtD
Sorafenib—Cardiac disorder—Zoledronate—Paget's disease of bone	0.00137	0.00178	CcSEcCtD
Sorafenib—Anaemia—Risedronate—Paget's disease of bone	0.00137	0.00178	CcSEcCtD
Sorafenib—Muscle spasms—Pamidronate—Paget's disease of bone	0.00136	0.00176	CcSEcCtD
Sorafenib—Angioedema—Risedronate—Paget's disease of bone	0.00136	0.00176	CcSEcCtD
Sorafenib—Angiopathy—Zoledronate—Paget's disease of bone	0.00134	0.00174	CcSEcCtD
Sorafenib—Immune system disorder—Zoledronate—Paget's disease of bone	0.00134	0.00173	CcSEcCtD
Sorafenib—Mediastinal disorder—Zoledronate—Paget's disease of bone	0.00133	0.00173	CcSEcCtD
Sorafenib—Syncope—Risedronate—Paget's disease of bone	0.00133	0.00172	CcSEcCtD
Sorafenib—Dyspepsia—Alendronate—Paget's disease of bone	0.00133	0.00172	CcSEcCtD
Sorafenib—Arrhythmia—Zoledronate—Paget's disease of bone	0.00132	0.00171	CcSEcCtD
Sorafenib—CDK7—HIV Infection—NUP205—Paget's disease of bone	0.00131	0.00576	CbGpPWpGaD
Sorafenib—Alopecia—Zoledronate—Paget's disease of bone	0.00131	0.00169	CcSEcCtD
Sorafenib—Hypersensitivity—Etidronic acid—Paget's disease of bone	0.00131	0.00169	CcSEcCtD
Sorafenib—Loss of consciousness—Risedronate—Paget's disease of bone	0.00131	0.00169	CcSEcCtD
Sorafenib—Anaemia—Pamidronate—Paget's disease of bone	0.0013	0.00169	CcSEcCtD
Sorafenib—Mental disorder—Zoledronate—Paget's disease of bone	0.0013	0.00168	CcSEcCtD
Sorafenib—Cough—Risedronate—Paget's disease of bone	0.0013	0.00168	CcSEcCtD
Sorafenib—BRAF—Senescence and Autophagy in Cancer—SQSTM1—Paget's disease of bone	0.00129	0.00568	CbGpPWpGaD
Sorafenib—Pain—Alendronate—Paget's disease of bone	0.00129	0.00167	CcSEcCtD
Sorafenib—Constipation—Alendronate—Paget's disease of bone	0.00129	0.00167	CcSEcCtD
Sorafenib—Angioedema—Pamidronate—Paget's disease of bone	0.00129	0.00167	CcSEcCtD
Sorafenib—Malnutrition—Zoledronate—Paget's disease of bone	0.00129	0.00167	CcSEcCtD
Sorafenib—Erythema—Zoledronate—Paget's disease of bone	0.00129	0.00167	CcSEcCtD
Sorafenib—MAP3K7—Signaling by Interleukins—INPP5D—Paget's disease of bone	0.00128	0.00564	CbGpPWpGaD
Sorafenib—Hypertension—Risedronate—Paget's disease of bone	0.00128	0.00166	CcSEcCtD
Sorafenib—Syncope—Pamidronate—Paget's disease of bone	0.00127	0.00164	CcSEcCtD
Sorafenib—Myalgia—Risedronate—Paget's disease of bone	0.00126	0.00164	CcSEcCtD
Sorafenib—Arthralgia—Risedronate—Paget's disease of bone	0.00126	0.00164	CcSEcCtD
Sorafenib—Leukopenia—Pamidronate—Paget's disease of bone	0.00126	0.00164	CcSEcCtD
Sorafenib—Dysgeusia—Zoledronate—Paget's disease of bone	0.00126	0.00163	CcSEcCtD
Sorafenib—Unspecified disorder of skin and subcutaneous tissue—Risedronate—Paget's disease of bone	0.00126	0.00163	CcSEcCtD
Sorafenib—Pruritus—Etidronic acid—Paget's disease of bone	0.00125	0.00162	CcSEcCtD
Sorafenib—RAF1—Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)—INPP5D—Paget's disease of bone	0.00124	0.00545	CbGpPWpGaD
Sorafenib—Loss of consciousness—Pamidronate—Paget's disease of bone	0.00124	0.00161	CcSEcCtD
Sorafenib—Muscle spasms—Zoledronate—Paget's disease of bone	0.00124	0.00161	CcSEcCtD
Sorafenib—Dry mouth—Risedronate—Paget's disease of bone	0.00124	0.0016	CcSEcCtD
Sorafenib—Gastrointestinal pain—Alendronate—Paget's disease of bone	0.00124	0.0016	CcSEcCtD
Sorafenib—Cough—Pamidronate—Paget's disease of bone	0.00123	0.00159	CcSEcCtD
Sorafenib—MAP2K5—EGF/EGFR Signaling Pathway—INPP5D—Paget's disease of bone	0.00123	0.00539	CbGpPWpGaD
Sorafenib—Hypertension—Pamidronate—Paget's disease of bone	0.00122	0.00158	CcSEcCtD
Sorafenib—Diarrhoea—Etidronic acid—Paget's disease of bone	0.00121	0.00157	CcSEcCtD
Sorafenib—MAP2K5—BDNF signaling pathway—SQSTM1—Paget's disease of bone	0.00121	0.00531	CbGpPWpGaD
Sorafenib—Infection—Risedronate—Paget's disease of bone	0.0012	0.00156	CcSEcCtD
Sorafenib—Arthralgia—Pamidronate—Paget's disease of bone	0.0012	0.00156	CcSEcCtD
Sorafenib—Myalgia—Pamidronate—Paget's disease of bone	0.0012	0.00156	CcSEcCtD
Sorafenib—Urticaria—Alendronate—Paget's disease of bone	0.0012	0.00155	CcSEcCtD
Sorafenib—Abdominal pain—Alendronate—Paget's disease of bone	0.00119	0.00155	CcSEcCtD
Sorafenib—Body temperature increased—Alendronate—Paget's disease of bone	0.00119	0.00155	CcSEcCtD
Sorafenib—Shock—Risedronate—Paget's disease of bone	0.00119	0.00154	CcSEcCtD
Sorafenib—Anaemia—Zoledronate—Paget's disease of bone	0.00119	0.00154	CcSEcCtD
Sorafenib—Nervous system disorder—Risedronate—Paget's disease of bone	0.00119	0.00154	CcSEcCtD
Sorafenib—Angioedema—Zoledronate—Paget's disease of bone	0.00118	0.00153	CcSEcCtD
Sorafenib—Skin disorder—Risedronate—Paget's disease of bone	0.00118	0.00152	CcSEcCtD
Sorafenib—Syncope—Zoledronate—Paget's disease of bone	0.00116	0.0015	CcSEcCtD
Sorafenib—Leukopenia—Zoledronate—Paget's disease of bone	0.00115	0.00149	CcSEcCtD
Sorafenib—Anaphylactic shock—Pamidronate—Paget's disease of bone	0.00115	0.00149	CcSEcCtD
Sorafenib—MAP3K7—Signaling by Interleukins—SQSTM1—Paget's disease of bone	0.00115	0.00505	CbGpPWpGaD
Sorafenib—Infection—Pamidronate—Paget's disease of bone	0.00114	0.00148	CcSEcCtD
Sorafenib—MAP3K7—TGF-beta Signaling Pathway—PML—Paget's disease of bone	0.00113	0.00498	CbGpPWpGaD
Sorafenib—Shock—Pamidronate—Paget's disease of bone	0.00113	0.00147	CcSEcCtD
Sorafenib—Loss of consciousness—Zoledronate—Paget's disease of bone	0.00113	0.00147	CcSEcCtD
Sorafenib—Nervous system disorder—Pamidronate—Paget's disease of bone	0.00113	0.00146	CcSEcCtD
Sorafenib—Thrombocytopenia—Pamidronate—Paget's disease of bone	0.00113	0.00146	CcSEcCtD
Sorafenib—Vomiting—Etidronic acid—Paget's disease of bone	0.00113	0.00146	CcSEcCtD
Sorafenib—Cough—Zoledronate—Paget's disease of bone	0.00113	0.00146	CcSEcCtD
Sorafenib—BRAF—Integrated Breast Cancer Pathway—PML—Paget's disease of bone	0.00112	0.00491	CbGpPWpGaD
Sorafenib—Rash—Etidronic acid—Paget's disease of bone	0.00112	0.00145	CcSEcCtD
Sorafenib—Dermatitis—Etidronic acid—Paget's disease of bone	0.00112	0.00145	CcSEcCtD
Sorafenib—Hypertension—Zoledronate—Paget's disease of bone	0.00111	0.00144	CcSEcCtD
Sorafenib—Hypersensitivity—Alendronate—Paget's disease of bone	0.00111	0.00144	CcSEcCtD
Sorafenib—Headache—Etidronic acid—Paget's disease of bone	0.00111	0.00144	CcSEcCtD
Sorafenib—ABCC4—Ectoderm Differentiation—TNFRSF11B—Paget's disease of bone	0.00111	0.00487	CbGpPWpGaD
Sorafenib—Musculoskeletal discomfort—Risedronate—Paget's disease of bone	0.0011	0.00143	CcSEcCtD
Sorafenib—Anorexia—Pamidronate—Paget's disease of bone	0.0011	0.00142	CcSEcCtD
Sorafenib—Arthralgia—Zoledronate—Paget's disease of bone	0.0011	0.00142	CcSEcCtD
Sorafenib—Myalgia—Zoledronate—Paget's disease of bone	0.0011	0.00142	CcSEcCtD
Sorafenib—Unspecified disorder of skin and subcutaneous tissue—Zoledronate—Paget's disease of bone	0.00109	0.00141	CcSEcCtD
Sorafenib—Asthenia—Alendronate—Paget's disease of bone	0.00108	0.0014	CcSEcCtD
Sorafenib—Dyspnoea—Risedronate—Paget's disease of bone	0.00108	0.0014	CcSEcCtD
Sorafenib—Dry mouth—Zoledronate—Paget's disease of bone	0.00107	0.00139	CcSEcCtD
Sorafenib—MAPK11—Cellular responses to stress—VCP—Paget's disease of bone	0.00107	0.00469	CbGpPWpGaD
Sorafenib—Pruritus—Alendronate—Paget's disease of bone	0.00107	0.00138	CcSEcCtD
Sorafenib—Dyspepsia—Risedronate—Paget's disease of bone	0.00107	0.00138	CcSEcCtD
Sorafenib—RAF1—B Cell Receptor Signaling Pathway—INPP5D—Paget's disease of bone	0.00106	0.00467	CbGpPWpGaD
Sorafenib—Nausea—Etidronic acid—Paget's disease of bone	0.00105	0.00136	CcSEcCtD
Sorafenib—Anaphylactic shock—Zoledronate—Paget's disease of bone	0.00105	0.00136	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Pamidronate—Paget's disease of bone	0.00105	0.00136	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Risedronate—Paget's disease of bone	0.00105	0.00135	CcSEcCtD
Sorafenib—Infection—Zoledronate—Paget's disease of bone	0.00105	0.00135	CcSEcCtD
Sorafenib—Fatigue—Risedronate—Paget's disease of bone	0.00104	0.00135	CcSEcCtD
Sorafenib—MAPK11—Regulation of toll-like receptor signaling pathway—SQSTM1—Paget's disease of bone	0.00104	0.00458	CbGpPWpGaD
Sorafenib—Pain—Risedronate—Paget's disease of bone	0.00104	0.00134	CcSEcCtD
Sorafenib—Constipation—Risedronate—Paget's disease of bone	0.00104	0.00134	CcSEcCtD
Sorafenib—Shock—Zoledronate—Paget's disease of bone	0.00104	0.00134	CcSEcCtD
Sorafenib—Diarrhoea—Alendronate—Paget's disease of bone	0.00103	0.00134	CcSEcCtD
Sorafenib—Nervous system disorder—Zoledronate—Paget's disease of bone	0.00103	0.00134	CcSEcCtD
Sorafenib—Thrombocytopenia—Zoledronate—Paget's disease of bone	0.00103	0.00133	CcSEcCtD
Sorafenib—Dyspnoea—Pamidronate—Paget's disease of bone	0.00103	0.00133	CcSEcCtD
Sorafenib—Skin disorder—Zoledronate—Paget's disease of bone	0.00102	0.00132	CcSEcCtD
Sorafenib—BRAF—EGF/EGFR Signaling Pathway—INPP5D—Paget's disease of bone	0.00102	0.00448	CbGpPWpGaD
Sorafenib—Dyspepsia—Pamidronate—Paget's disease of bone	0.00101	0.00131	CcSEcCtD
Sorafenib—Anorexia—Zoledronate—Paget's disease of bone	0.001	0.0013	CcSEcCtD
Sorafenib—Decreased appetite—Pamidronate—Paget's disease of bone	0.001	0.0013	CcSEcCtD
Sorafenib—Dizziness—Alendronate—Paget's disease of bone	0.000999	0.00129	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Pamidronate—Paget's disease of bone	0.000995	0.00129	CcSEcCtD
Sorafenib—Fatigue—Pamidronate—Paget's disease of bone	0.000993	0.00129	CcSEcCtD
Sorafenib—Gastrointestinal pain—Risedronate—Paget's disease of bone	0.000991	0.00128	CcSEcCtD
Sorafenib—CDK7—Cell Cycle, Mitotic—OPTN—Paget's disease of bone	0.000986	0.00433	CbGpPWpGaD
Sorafenib—Constipation—Pamidronate—Paget's disease of bone	0.000985	0.00128	CcSEcCtD
Sorafenib—Pain—Pamidronate—Paget's disease of bone	0.000985	0.00128	CcSEcCtD
Sorafenib—RAF1—Signaling by Interleukins—INPP5D—Paget's disease of bone	0.000976	0.00429	CbGpPWpGaD
Sorafenib—Urticaria—Risedronate—Paget's disease of bone	0.000963	0.00125	CcSEcCtD
Sorafenib—Vomiting—Alendronate—Paget's disease of bone	0.00096	0.00124	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Zoledronate—Paget's disease of bone	0.000959	0.00124	CcSEcCtD
Sorafenib—Body temperature increased—Risedronate—Paget's disease of bone	0.000958	0.00124	CcSEcCtD
Sorafenib—Abdominal pain—Risedronate—Paget's disease of bone	0.000958	0.00124	CcSEcCtD
Sorafenib—Rash—Alendronate—Paget's disease of bone	0.000952	0.00123	CcSEcCtD
Sorafenib—Dermatitis—Alendronate—Paget's disease of bone	0.000951	0.00123	CcSEcCtD
Sorafenib—Headache—Alendronate—Paget's disease of bone	0.000946	0.00123	CcSEcCtD
Sorafenib—Gastrointestinal pain—Pamidronate—Paget's disease of bone	0.000942	0.00122	CcSEcCtD
Sorafenib—MAP3K7—Regulation of toll-like receptor signaling pathway—SQSTM1—Paget's disease of bone	0.000941	0.00413	CbGpPWpGaD
Sorafenib—Dyspnoea—Zoledronate—Paget's disease of bone	0.000938	0.00121	CcSEcCtD
Sorafenib—Dyspepsia—Zoledronate—Paget's disease of bone	0.000926	0.0012	CcSEcCtD
Sorafenib—Decreased appetite—Zoledronate—Paget's disease of bone	0.000915	0.00118	CcSEcCtD
Sorafenib—Abdominal pain—Pamidronate—Paget's disease of bone	0.000911	0.00118	CcSEcCtD
Sorafenib—Body temperature increased—Pamidronate—Paget's disease of bone	0.000911	0.00118	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Zoledronate—Paget's disease of bone	0.000908	0.00118	CcSEcCtD
Sorafenib—Fatigue—Zoledronate—Paget's disease of bone	0.000907	0.00117	CcSEcCtD
Sorafenib—Constipation—Zoledronate—Paget's disease of bone	0.0009	0.00117	CcSEcCtD
Sorafenib—Pain—Zoledronate—Paget's disease of bone	0.0009	0.00117	CcSEcCtD
Sorafenib—EPHX2—Metabolism of lipids and lipoproteins—INPP5D—Paget's disease of bone	0.000897	0.00394	CbGpPWpGaD
Sorafenib—Nausea—Alendronate—Paget's disease of bone	0.000897	0.00116	CcSEcCtD
Sorafenib—RAF1—Senescence and Autophagy in Cancer—SQSTM1—Paget's disease of bone	0.000895	0.00393	CbGpPWpGaD
Sorafenib—Hypersensitivity—Risedronate—Paget's disease of bone	0.000893	0.00116	CcSEcCtD
Sorafenib—CDK7—Cell Cycle—OPTN—Paget's disease of bone	0.000882	0.00387	CbGpPWpGaD
Sorafenib—RAF1—Signaling by Interleukins—SQSTM1—Paget's disease of bone	0.000875	0.00384	CbGpPWpGaD
Sorafenib—RAF1—BDNF signaling pathway—ALPL—Paget's disease of bone	0.000873	0.00383	CbGpPWpGaD
Sorafenib—Asthenia—Risedronate—Paget's disease of bone	0.00087	0.00113	CcSEcCtD
Sorafenib—RAF1—TGF-beta Signaling Pathway—PML—Paget's disease of bone	0.000862	0.00378	CbGpPWpGaD
Sorafenib—Gastrointestinal pain—Zoledronate—Paget's disease of bone	0.00086	0.00111	CcSEcCtD
Sorafenib—Pruritus—Risedronate—Paget's disease of bone	0.000857	0.00111	CcSEcCtD
Sorafenib—Hypersensitivity—Pamidronate—Paget's disease of bone	0.000849	0.0011	CcSEcCtD
Sorafenib—Urticaria—Zoledronate—Paget's disease of bone	0.000836	0.00108	CcSEcCtD
Sorafenib—Abdominal pain—Zoledronate—Paget's disease of bone	0.000832	0.00108	CcSEcCtD
Sorafenib—Body temperature increased—Zoledronate—Paget's disease of bone	0.000832	0.00108	CcSEcCtD
Sorafenib—Diarrhoea—Risedronate—Paget's disease of bone	0.000829	0.00107	CcSEcCtD
Sorafenib—Asthenia—Pamidronate—Paget's disease of bone	0.000827	0.00107	CcSEcCtD
Sorafenib—ABCC4—NRF2 pathway—SQSTM1—Paget's disease of bone	0.000818	0.00359	CbGpPWpGaD
Sorafenib—Pruritus—Pamidronate—Paget's disease of bone	0.000815	0.00106	CcSEcCtD
Sorafenib—MAPK11—Metabolism of RNA—NUP205—Paget's disease of bone	0.000812	0.00357	CbGpPWpGaD
Sorafenib—Dizziness—Risedronate—Paget's disease of bone	0.000801	0.00104	CcSEcCtD
Sorafenib—FGFR1—Integrated Pancreatic Cancer Pathway—PML—Paget's disease of bone	0.0008	0.00352	CbGpPWpGaD
Sorafenib—PDGFRA—Integrated Pancreatic Cancer Pathway—PML—Paget's disease of bone	0.000798	0.00351	CbGpPWpGaD
Sorafenib—Diarrhoea—Pamidronate—Paget's disease of bone	0.000788	0.00102	CcSEcCtD
Sorafenib—Hypersensitivity—Zoledronate—Paget's disease of bone	0.000775	0.001	CcSEcCtD
Sorafenib—Vomiting—Risedronate—Paget's disease of bone	0.000771	0.000998	CcSEcCtD
Sorafenib—Rash—Risedronate—Paget's disease of bone	0.000764	0.000989	CcSEcCtD
Sorafenib—Dermatitis—Risedronate—Paget's disease of bone	0.000763	0.000989	CcSEcCtD
Sorafenib—Dizziness—Pamidronate—Paget's disease of bone	0.000762	0.000986	CcSEcCtD
Sorafenib—Headache—Risedronate—Paget's disease of bone	0.000759	0.000983	CcSEcCtD
Sorafenib—Asthenia—Zoledronate—Paget's disease of bone	0.000755	0.000978	CcSEcCtD
Sorafenib—Pruritus—Zoledronate—Paget's disease of bone	0.000745	0.000964	CcSEcCtD
Sorafenib—Vomiting—Pamidronate—Paget's disease of bone	0.000732	0.000948	CcSEcCtD
Sorafenib—Rash—Pamidronate—Paget's disease of bone	0.000726	0.000941	CcSEcCtD
Sorafenib—Dermatitis—Pamidronate—Paget's disease of bone	0.000726	0.00094	CcSEcCtD
Sorafenib—Headache—Pamidronate—Paget's disease of bone	0.000722	0.000935	CcSEcCtD
Sorafenib—Diarrhoea—Zoledronate—Paget's disease of bone	0.00072	0.000932	CcSEcCtD
Sorafenib—Nausea—Risedronate—Paget's disease of bone	0.00072	0.000932	CcSEcCtD
Sorafenib—UGT1A1—NRF2 pathway—SQSTM1—Paget's disease of bone	0.000707	0.0031	CbGpPWpGaD
Sorafenib—UGT1A9—NRF2 pathway—SQSTM1—Paget's disease of bone	0.000707	0.0031	CbGpPWpGaD
Sorafenib—RAF1—EGF/EGFR Signaling Pathway—INPP5D—Paget's disease of bone	0.000706	0.0031	CbGpPWpGaD
Sorafenib—MAP3K7—Cytokine Signaling in Immune system—NUP205—Paget's disease of bone	0.000703	0.00309	CbGpPWpGaD
Sorafenib—CDK7—Cell Cycle, Mitotic—NUP205—Paget's disease of bone	0.000701	0.00308	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling by NGF—SQSTM1—Paget's disease of bone	0.000699	0.00307	CbGpPWpGaD
Sorafenib—Dizziness—Zoledronate—Paget's disease of bone	0.000696	0.000901	CcSEcCtD
Sorafenib—RAF1—BDNF signaling pathway—SQSTM1—Paget's disease of bone	0.000695	0.00305	CbGpPWpGaD
Sorafenib—ABCC2—NRF2 pathway—SQSTM1—Paget's disease of bone	0.000689	0.00303	CbGpPWpGaD
Sorafenib—Nausea—Pamidronate—Paget's disease of bone	0.000684	0.000886	CcSEcCtD
Sorafenib—Vomiting—Zoledronate—Paget's disease of bone	0.000669	0.000866	CcSEcCtD
Sorafenib—Rash—Zoledronate—Paget's disease of bone	0.000663	0.000859	CcSEcCtD
Sorafenib—Dermatitis—Zoledronate—Paget's disease of bone	0.000663	0.000858	CcSEcCtD
Sorafenib—Headache—Zoledronate—Paget's disease of bone	0.000659	0.000854	CcSEcCtD
Sorafenib—RAF1—Integrated Pancreatic Cancer Pathway—PML—Paget's disease of bone	0.000641	0.00282	CbGpPWpGaD
Sorafenib—CDK7—Cell Cycle—NUP205—Paget's disease of bone	0.000627	0.00275	CbGpPWpGaD
Sorafenib—Nausea—Zoledronate—Paget's disease of bone	0.000625	0.000809	CcSEcCtD
Sorafenib—MAP3K7—Cytokine Signaling in Immune system—PML—Paget's disease of bone	0.000621	0.00273	CbGpPWpGaD
Sorafenib—MAP3K7—Cytokine Signaling in Immune system—INPP5D—Paget's disease of bone	0.000599	0.00263	CbGpPWpGaD
Sorafenib—MKNK1—Disease—VCP—Paget's disease of bone	0.000597	0.00262	CbGpPWpGaD
Sorafenib—MAPK11—Signaling by NGF—SQSTM1—Paget's disease of bone	0.000586	0.00257	CbGpPWpGaD
Sorafenib—BRAF—Signaling by NGF—SQSTM1—Paget's disease of bone	0.00058	0.00255	CbGpPWpGaD
Sorafenib—MAP3K7—Cytokine Signaling in Immune system—SQSTM1—Paget's disease of bone	0.000537	0.00236	CbGpPWpGaD
Sorafenib—RAF1—Cytokine Signaling in Immune system—NUP205—Paget's disease of bone	0.000534	0.00235	CbGpPWpGaD
Sorafenib—KIT—Signaling by NGF—SQSTM1—Paget's disease of bone	0.000528	0.00232	CbGpPWpGaD
Sorafenib—RALBP1—Signaling Pathways—VCP—Paget's disease of bone	0.000513	0.00225	CbGpPWpGaD
Sorafenib—FLT4—Signaling Pathways—VCP—Paget's disease of bone	0.000504	0.00222	CbGpPWpGaD
Sorafenib—FGFR1—Signaling by NGF—SQSTM1—Paget's disease of bone	0.000501	0.0022	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling by NGF—SQSTM1—Paget's disease of bone	0.0005	0.0022	CbGpPWpGaD
Sorafenib—RAF1—Cytokine Signaling in Immune system—PML—Paget's disease of bone	0.000472	0.00207	CbGpPWpGaD
Sorafenib—EPHX2—Metabolism—NUP205—Paget's disease of bone	0.000469	0.00206	CbGpPWpGaD
Sorafenib—MKNK1—Disease—NUP205—Paget's disease of bone	0.000456	0.002	CbGpPWpGaD
Sorafenib—RAF1—Cytokine Signaling in Immune system—INPP5D—Paget's disease of bone	0.000455	0.002	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling by NGF—SQSTM1—Paget's disease of bone	0.00045	0.00198	CbGpPWpGaD
Sorafenib—CDK7—Disease—VCP—Paget's disease of bone	0.000421	0.00185	CbGpPWpGaD
Sorafenib—MKNK1—Signaling Pathways—VCP—Paget's disease of bone	0.000418	0.00184	CbGpPWpGaD
Sorafenib—RAF1—Cytokine Signaling in Immune system—SQSTM1—Paget's disease of bone	0.000408	0.00179	CbGpPWpGaD
Sorafenib—RAF1—Signaling by NGF—SQSTM1—Paget's disease of bone	0.000401	0.00176	CbGpPWpGaD
Sorafenib—EPHX2—Metabolism—INPP5D—Paget's disease of bone	0.0004	0.00175	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—VCP—Paget's disease of bone	0.000376	0.00165	CbGpPWpGaD
Sorafenib—CDK7—Gene Expression—NUP205—Paget's disease of bone	0.000346	0.00152	CbGpPWpGaD
Sorafenib—ABCC4—Transmembrane transport of small molecules—NUP205—Paget's disease of bone	0.000343	0.0015	CbGpPWpGaD
Sorafenib—MKNK1—Disease—CALCA—Paget's disease of bone	0.000339	0.00149	CbGpPWpGaD
Sorafenib—ABCC4—Hemostasis—INPP5D—Paget's disease of bone	0.000337	0.00148	CbGpPWpGaD
Sorafenib—KIT—Adaptive Immune System—INPP5D—Paget's disease of bone	0.000323	0.00142	CbGpPWpGaD
Sorafenib—MAP3K7—Adaptive Immune System—INPP5D—Paget's disease of bone	0.000323	0.00142	CbGpPWpGaD
Sorafenib—CDK7—Disease—NUP205—Paget's disease of bone	0.000321	0.00141	CbGpPWpGaD
Sorafenib—FGFR1—Adaptive Immune System—INPP5D—Paget's disease of bone	0.000306	0.00134	CbGpPWpGaD
Sorafenib—PDGFRA—Adaptive Immune System—INPP5D—Paget's disease of bone	0.000305	0.00134	CbGpPWpGaD
Sorafenib—BRAF—Disease—VCP—Paget's disease of bone	0.000305	0.00134	CbGpPWpGaD
Sorafenib—ABCB1—Integrated Pancreatic Cancer Pathway—PML—Paget's disease of bone	0.000302	0.00133	CbGpPWpGaD
Sorafenib—RALBP1—Signaling Pathways—SQSTM1—Paget's disease of bone	0.0003	0.00132	CbGpPWpGaD
Sorafenib—HTR2B—GPCR ligand binding—CALCA—Paget's disease of bone	0.000296	0.0013	CbGpPWpGaD
Sorafenib—FLT4—Signaling Pathways—SQSTM1—Paget's disease of bone	0.000295	0.00129	CbGpPWpGaD
Sorafenib—RALBP1—Signaling Pathways—CALCA—Paget's disease of bone	0.000291	0.00128	CbGpPWpGaD
Sorafenib—ABCC2—Transmembrane transport of small molecules—NUP205—Paget's disease of bone	0.000289	0.00127	CbGpPWpGaD
Sorafenib—RAF1—Transmembrane transport of small molecules—NUP205—Paget's disease of bone	0.000288	0.00126	CbGpPWpGaD
Sorafenib—FLT4—Signaling Pathways—CALCA—Paget's disease of bone	0.000286	0.00126	CbGpPWpGaD
Sorafenib—RAF1—Hemostasis—INPP5D—Paget's disease of bone	0.000284	0.00125	CbGpPWpGaD
Sorafenib—KIT—Disease—VCP—Paget's disease of bone	0.000277	0.00122	CbGpPWpGaD
Sorafenib—PDGFRB—Adaptive Immune System—INPP5D—Paget's disease of bone	0.000275	0.00121	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism of lipids and lipoproteins—INPP5D—Paget's disease of bone	0.000265	0.00117	CbGpPWpGaD
Sorafenib—FGFR1—Disease—VCP—Paget's disease of bone	0.000263	0.00116	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—VCP—Paget's disease of bone	0.000262	0.00115	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—VCP—Paget's disease of bone	0.000257	0.00113	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—NUP205—Paget's disease of bone	0.000255	0.00112	CbGpPWpGaD
Sorafenib—MAPK11—Gene Expression—NUP205—Paget's disease of bone	0.000253	0.00111	CbGpPWpGaD
Sorafenib—ABCG2—Transmembrane transport of small molecules—NUP205—Paget's disease of bone	0.000251	0.0011	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—VCP—Paget's disease of bone	0.00025	0.0011	CbGpPWpGaD
Sorafenib—RAF1—Adaptive Immune System—INPP5D—Paget's disease of bone	0.000245	0.00108	CbGpPWpGaD
Sorafenib—MKNK1—Signaling Pathways—SQSTM1—Paget's disease of bone	0.000244	0.00107	CbGpPWpGaD
Sorafenib—CDK7—Disease—CALCA—Paget's disease of bone	0.000239	0.00105	CbGpPWpGaD
Sorafenib—HTR2C—GPCR ligand binding—CALCA—Paget's disease of bone	0.000238	0.00105	CbGpPWpGaD
Sorafenib—MKNK1—Signaling Pathways—CALCA—Paget's disease of bone	0.000237	0.00104	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—VCP—Paget's disease of bone	0.000236	0.00104	CbGpPWpGaD
Sorafenib—BRAF—Disease—NUP205—Paget's disease of bone	0.000233	0.00102	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—NUP205—Paget's disease of bone	0.00023	0.00101	CbGpPWpGaD
Sorafenib—KIT—Immune System—NUP205—Paget's disease of bone	0.00023	0.00101	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—PML—Paget's disease of bone	0.000225	0.000988	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—SQSTM1—Paget's disease of bone	0.00022	0.000966	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—NUP205—Paget's disease of bone	0.000218	0.000957	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—NUP205—Paget's disease of bone	0.000217	0.000954	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—INPP5D—Paget's disease of bone	0.000217	0.000953	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—VCP—Paget's disease of bone	0.000215	0.000946	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—CALCA—Paget's disease of bone	0.000214	0.000938	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—VCP—Paget's disease of bone	0.000213	0.000937	CbGpPWpGaD
Sorafenib—KIT—Disease—NUP205—Paget's disease of bone	0.000212	0.000931	CbGpPWpGaD
Sorafenib—RAF1—Disease—VCP—Paget's disease of bone	0.000211	0.000925	CbGpPWpGaD
Sorafenib—KIT—Immune System—PML—Paget's disease of bone	0.000203	0.000891	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—PML—Paget's disease of bone	0.000203	0.000891	CbGpPWpGaD
Sorafenib—FGFR1—Disease—NUP205—Paget's disease of bone	0.000201	0.000883	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—NUP205—Paget's disease of bone	0.000201	0.000881	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—NUP205—Paget's disease of bone	0.000196	0.00086	CbGpPWpGaD
Sorafenib—KIT—Immune System—INPP5D—Paget's disease of bone	0.000196	0.000859	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—INPP5D—Paget's disease of bone	0.000196	0.000859	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—SQSTM1—Paget's disease of bone	0.000195	0.000854	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—VCP—Paget's disease of bone	0.000194	0.000853	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—VCP—Paget's disease of bone	0.000194	0.000853	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—PML—Paget's disease of bone	0.000193	0.000845	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—PML—Paget's disease of bone	0.000192	0.000843	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—INPP5D—Paget's disease of bone	0.000186	0.000816	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—INPP5D—Paget's disease of bone	0.000185	0.000814	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—VCP—Paget's disease of bone	0.000184	0.000809	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—VCP—Paget's disease of bone	0.000184	0.000807	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—NUP205—Paget's disease of bone	0.000181	0.000794	CbGpPWpGaD
Sorafenib—KIT—Immune System—SQSTM1—Paget's disease of bone	0.000175	0.00077	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—SQSTM1—Paget's disease of bone	0.000175	0.00077	CbGpPWpGaD
Sorafenib—RAF1—Immune System—NUP205—Paget's disease of bone	0.000174	0.000766	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—PML—Paget's disease of bone	0.000173	0.00076	CbGpPWpGaD
Sorafenib—BRAF—Disease—CALCA—Paget's disease of bone	0.000173	0.000759	CbGpPWpGaD
Sorafenib—HTR2B—GPCR downstream signaling—CALCA—Paget's disease of bone	0.000167	0.000733	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—INPP5D—Paget's disease of bone	0.000167	0.000733	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—SQSTM1—Paget's disease of bone	0.000167	0.000731	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—SQSTM1—Paget's disease of bone	0.000166	0.000729	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—VCP—Paget's disease of bone	0.000166	0.000727	CbGpPWpGaD
Sorafenib—RAF1—Disease—NUP205—Paget's disease of bone	0.000161	0.000707	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—VCP—Paget's disease of bone	0.000158	0.000693	CbGpPWpGaD
Sorafenib—KIT—Disease—CALCA—Paget's disease of bone	0.000157	0.000691	CbGpPWpGaD
Sorafenib—RAF1—Immune System—PML—Paget's disease of bone	0.000154	0.000677	CbGpPWpGaD
Sorafenib—HTR2B—Signaling by GPCR—CALCA—Paget's disease of bone	0.000152	0.000666	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—SQSTM1—Paget's disease of bone	0.00015	0.000659	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—SQSTM1—Paget's disease of bone	0.00015	0.000657	CbGpPWpGaD
Sorafenib—FGFR1—Disease—CALCA—Paget's disease of bone	0.000149	0.000656	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—CALCA—Paget's disease of bone	0.000149	0.000654	CbGpPWpGaD
Sorafenib—RAF1—Immune System—INPP5D—Paget's disease of bone	0.000149	0.000653	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—VCP—Paget's disease of bone	0.000148	0.000648	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—SQSTM1—Paget's disease of bone	0.000146	0.000642	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—CALCA—Paget's disease of bone	0.000146	0.00064	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—CALCA—Paget's disease of bone	0.000142	0.000624	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—CALCA—Paget's disease of bone	0.000142	0.000622	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism of lipids and lipoproteins—INPP5D—Paget's disease of bone	0.00014	0.000614	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—NUP205—Paget's disease of bone	0.000139	0.000609	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—NUP205—Paget's disease of bone	0.000139	0.000609	CbGpPWpGaD
Sorafenib—ABCB1—Transmembrane transport of small molecules—NUP205—Paget's disease of bone	0.000136	0.000596	CbGpPWpGaD
Sorafenib—HTR2C—GPCR downstream signaling—CALCA—Paget's disease of bone	0.000135	0.000592	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—CALCA—Paget's disease of bone	0.000134	0.000589	CbGpPWpGaD
Sorafenib—RAF1—Immune System—SQSTM1—Paget's disease of bone	0.000133	0.000586	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—VCP—Paget's disease of bone	0.000127	0.000559	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—SQSTM1—Paget's disease of bone	0.000126	0.000552	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism of lipids and lipoproteins—INPP5D—Paget's disease of bone	0.000125	0.000548	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—SQSTM1—Paget's disease of bone	0.000125	0.000547	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—CALCA—Paget's disease of bone	0.000122	0.000537	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—CALCA—Paget's disease of bone	0.000122	0.000536	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—CALCA—Paget's disease of bone	0.000121	0.000531	CbGpPWpGaD
Sorafenib—RAF1—Disease—CALCA—Paget's disease of bone	0.00012	0.000525	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—INPP5D—Paget's disease of bone	0.000118	0.000519	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—INPP5D—Paget's disease of bone	0.000118	0.000519	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—NUP205—Paget's disease of bone	0.000118	0.000517	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—NUP205—Paget's disease of bone	0.000117	0.000512	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism of lipids and lipoproteins—INPP5D—Paget's disease of bone	0.000114	0.0005	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—SQSTM1—Paget's disease of bone	0.000113	0.000498	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—SQSTM1—Paget's disease of bone	0.000113	0.000498	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—CALCA—Paget's disease of bone	0.00011	0.000484	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—CALCA—Paget's disease of bone	0.00011	0.000484	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—SQSTM1—Paget's disease of bone	0.000108	0.000473	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—SQSTM1—Paget's disease of bone	0.000107	0.000472	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—CALCA—Paget's disease of bone	0.000105	0.000459	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—CALCA—Paget's disease of bone	0.000104	0.000458	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—INPP5D—Paget's disease of bone	0.0001	0.000441	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—INPP5D—Paget's disease of bone	9.94e-05	0.000437	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism of lipids and lipoproteins—INPP5D—Paget's disease of bone	9.72e-05	0.000427	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—SQSTM1—Paget's disease of bone	9.67e-05	0.000425	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—CALCA—Paget's disease of bone	9.39e-05	0.000413	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—SQSTM1—Paget's disease of bone	9.23e-05	0.000405	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—CALCA—Paget's disease of bone	8.96e-05	0.000393	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—NUP205—Paget's disease of bone	8.62e-05	0.000379	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—SQSTM1—Paget's disease of bone	8.62e-05	0.000379	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—NUP205—Paget's disease of bone	8.43e-05	0.00037	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—CALCA—Paget's disease of bone	8.37e-05	0.000368	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—SQSTM1—Paget's disease of bone	7.44e-05	0.000327	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—INPP5D—Paget's disease of bone	7.35e-05	0.000323	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—NUP205—Paget's disease of bone	7.3e-05	0.000321	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CALCA—Paget's disease of bone	7.23e-05	0.000317	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—INPP5D—Paget's disease of bone	7.19e-05	0.000316	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—NUP205—Paget's disease of bone	6.52e-05	0.000286	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—NUP205—Paget's disease of bone	6.36e-05	0.000279	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—INPP5D—Paget's disease of bone	6.23e-05	0.000273	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—NUP205—Paget's disease of bone	5.99e-05	0.000263	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—NUP205—Paget's disease of bone	5.94e-05	0.000261	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—INPP5D—Paget's disease of bone	5.56e-05	0.000244	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—INPP5D—Paget's disease of bone	5.42e-05	0.000238	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—INPP5D—Paget's disease of bone	5.11e-05	0.000224	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—NUP205—Paget's disease of bone	5.08e-05	0.000223	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—INPP5D—Paget's disease of bone	5.07e-05	0.000223	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—INPP5D—Paget's disease of bone	4.33e-05	0.00019	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—NUP205—Paget's disease of bone	3.92e-05	0.000172	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—INPP5D—Paget's disease of bone	3.34e-05	0.000147	CbGpPWpGaD
